Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Bimekizumab in Pediatric Patients With Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis
NCT06668181Phase 3Recruiting
- Sponsor
- UCB
- Start
- Mar 2025
- Primary completion
- Apr 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 3 trial of bimekizumab in enthesitis-related juvenile idiopathic arthritis (ERA), juvenile psoriatic arthritis (JPsA), sponsored by UCB. Started Mar 2025; status: recruiting.
02
Drugs
bimekizumab
03
Conditions
enthesitis-related juvenile idiopathic arthritis (ERA)juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NCT06668181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668181.